|
|
Article: In a New Observational Analysis, Risedronate Significantly Reduced Nonvertebral Fracture Risk Compared to Alendronate and Nasal Calcitonin At One Year; Risk of Nonvertebral Fracture Was 59 Percent Lower With Risedronate Compared To Alendronate.
- Article from:
- PR Newswire
- Article date:
- September 22, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MINNEAPOLIS, Sept. 22 /PRNewswire/ -- In a new observational analysis presented at the 25th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR), osteoporosis patients taking risedronate (Actonel(R)) had a 59 percent (p=0.04) lower risk of nonvertebral fracture than patients receiving alendronate (Fosamax(R)) and a 75 percent (p
"Fracture reduction is the clinically relevant endpoint for evaluating osteoporosis therapies," said Nelson B. Watts, MD, presenting author and Director, University of Cincinnati Bone Health and Osteoporosis Center. "While only head-to-head clinical trials comparing fracture efficacy can confirm differences in efficacy ...